ME
ALT icon

McIlrath & Eck’s Altimmune ALT Stock Holding History

McIlrath & Eck’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-2
Closed -$33 – 925
2022
Q4 		$33 Buy
+2
New +$22 ﹤0.01% 879

Other funds holding ALT

N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

McIlrath & Eck's ALT Position: Q1 2023 in Review

McIlrath & Eck sold out of Altimmune (ALT) in Q1 2023, closing a stake of 2 shares — an estimated $33 sold.

McIlrath & Eck first reported a position in ALT in Q4 2022 and held it in 1 quarter. The position peaked at $33 in Q4 2022. 132 funds tracked by Wall St. Rank hold ALT as of Q1 2023.

  • McIlrath & Eck reported no remaining Altimmune position as of Q1 2023 after selling out during the quarter.
  • McIlrath & Eck sold 2 Altimmune shares in Q1 2023, an estimated $33.
  • McIlrath & Eck first reported a position in Altimmune in Q4 2022 and held it in 1 quarter.
  • McIlrath & Eck's Altimmune position peaked at $33 in Q4 2022.
  • 132 funds tracked by Wall St. Rank held Altimmune as of Q1 2023.

Based on McIlrath & Eck's 13F filing for Q1 2023, filed 9 May 2023.